Development of new glutaminase inhibitors with potential antitumor action

Vol. 1, 2019 - 109168
Poster only
Favorite this paper
How to cite this paper?
Abstract

The Negative Triple Breast Cancer (TNBC), characterized by low expression/absence of detection of hormonal receptors estrogen (ER), progesterone (PR) and growth factors (Her2) is the most common among young women, has the worst prognosis and aggressive characteristics.
Reprogramming the metabolism in tumor cells may provide targets for the treatment of cancer. In TNBC, glutaminase, the first route of metabolism of the glutamine amino acid, has emerged as a promising target.
We evaluated promising compounds in cellular and enzymatic assays to assess tumor selective cytotoxicity and action on the target.
We found that C12 and C15.1 (ChembridgeDIVERSet™ Library) shows promising biochemical results (graphs C and D), and are under further analysis and remodeling of the molecules.
TNBC-MDA-MB-231 and Non-TNBC-SKBR3 cell lines were used, and Glutaminase C (GAC) and Glutamate Dehydrogenase (GDH) were the studied enzymes.

Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
Triple-Negative Breast Cancer
Glutaminase
Glutamate Dehydrogenase